Overview

Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

Status:
Recruiting

Trial end date:
2023-06-30

Target enrollment:

Participant gender:

Summary

This is a randomized, open-label, controlled, multicenter, phase III trial to compare the efficacy and safety of Toripalimab in combination with axitinib to sunitinib monotherapy as a first-line therapy for advanced RCC. Eligible patients will be randomized 1:1 to receive the combination therapy of Toripalimab and axitinib or sunitinib monotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Shanghai Junshi Bioscience Co., Ltd.

Treatments:

Axitinib
Sunitinib